Brief: Cannabics Prepares To Submit FDA With Pre-IND Meeting Request For Proprietary Colon Cancer Drug Candidate
21/10/2020 14:21
Oct 21 (Reuters) - Cannabics Pharmaceuticals Inc CNBX.PK :
* CANNABICS PHARMACEUTICALS PREPARES TO SUBMIT THE FDA WITH
A
PRE-IND MEETING REQUEST FOR ITS PROPRIETARY COLON CANCER DRUG
CANDIDATE, CANNABICS™ RCC-33
* CANNABICS PHARMACEUTICALS - PRE-IND MEETING REQUEST WITH
FDA IS
EXPECTED TO BE SUBMITTED DURING Q1 2021 & SUBSEQUENTLY TAKE
PLACE IN FIRST HALF OF 2021.
Source text for Eikon: ID:nPn9GRMF5a
Further company coverage: CNBX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CNBX Pharmaceuticals
See all newsBrief: Cannabics Pharmaceuticals Appoints Second Independent Board Member
Brief: Cannabics Prepares To Submit FDA With Pre-IND Meeting Request For Proprietary Colon Cancer Drug Candidate
Brief: Cannabics Pharmaceuticals Appoints Dr. Dana Ben-Ami Shor To Its Scientific Board Of Advisors
Brief: Cannabics Pharmaceuticals Initiates Entry For Its Cannabinoid Diagnostic Platform Into European Markets
Brief: Cannabics Pharmaceuticals & Cannomed Collaborate To Develop Cannabis Strains Targeting Cancers